Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
J. Clin. Invest. Jun Wang, et al. 117:3393 doi:10.1172/JCI31547 [Go to this article.]

Figure 1
Valsartan prevents oligomerization of Aβ_1–42 peptide into a HMW Aβ species in vitro. (A) Western blot analysis of Aβ_1–42 oligomers in the presence of losartan, valsartan, carvedilol, hydralazine, propranolol, nicardipine, or amiloride. Bands at 3.5 kDa represent the monomeric Aβ form, whereas the smear between 55 and 130 kDa represents the oligomeric form of Aβ. (B) Valsartan decreases the accumulation of HMW Aβ_1–42 species. Inset: Nonaggregated Aβ_1–42 control (lane 1). Representative Western immunoblot of Aβ_1–42 in the absence (lane 2) or presence of 10 μM valsartan (lane 3). (C) Quantitative dot blot analysis of valsartan inhibition of Aβ_1–42 oligomerization. The same samples used in B were subjected to dot blot analysis using oligomer-specific antibody A11. Inset: Representative dot blot image. Results are expressed as percent of negative control (negative control presents nonaggregated Aβ), and values represent mean ± SEM. *P < 0.05.